Table 2. Comparison of baseline with month 12 outcomes for combined study group to ranibizumab (N=36).
| Outcome variable | Baseline mean (SD) aMedian | Month 12 Mean (SD) aMedian | P-value |
|---|---|---|---|
| BCVA, LogMAR | 0.57 (0.19) | 0.46 (0.36) | 0.04 |
| Contrast sensitivity | 26.16 (5.84) | 26.75 (8.04) | 0.54 |
| PED GLD, μm | 4081.65 (1172.12) | 3116.28 (1350.95) | <0.001 |
| PED SA, mm2 | 10.42 (6.08) | 6.40 (4.75) | <0.001 |
| CNV GLD, μm | 2044.29 (1227.84) | 1559.86 (1179.99) | 0.055 |
| CNV SA, mm2 | 2.76 (3.06) | 1.44 (2.10) | 0.001 |
| PED height, μm | 425.53 (176.72) | 208.45 (153.43) | <0.001 |
| Central 1-mm thickness, μm | 306.92 (83.77) | 213.89 (56.68) | <0.001 |
| SRF | 2.00a | 0a | <0.001 |
| CME | 1.00a | 0a | <0.001 |
Abbreviations: BCVA, best-corrected visual acuity; CME, cystoid macular edema; GLD, greatest linear diameter; logMar, logarithm10 reciprocal of snellen visual acuity equivalent; LS, early treatment diabetic retinopathy study letter scores; PED, pigment epithelial detachment; SA, surface area; SD, standard deviation; SRF, subretinal fluid.
Wilcoxon Signed-Rank test performed for comparison for SRF and CME; Paired Samples